Gleevec

(redirected from Imatinib mesylate)
Also found in: Medical.

Glee·vec

 (glē′vĕk)
A trademark for the mesylate form of imatinib.
References in periodicals archive ?
Imatinib mesylate is the primary treatment at the onset of the disease in patients with recurrent, metastatic, or unresectable GISTs.
Tenders are invited for Imatinib mesylate 100mg cap
Cancer medicines company Mylan NV (Nasdaq:MYL)(TASE:MYL) reported on Friday the availability of Imatinib Mesylate Tablets in 100 mg and 400 mg.
M2 EQUITYBITES-October 2, 2017-Mylan launches Imatinib Mesylate Tablets in US
Imatinib mesylate (Glivec[R], STI 571; Novartis Pharma, Switzerland), an antitumor agent has been widely used to treat multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and gastrointestinal stromal tumors.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
product known by its chemical name of imatinib mesylate.
The company is expected to launch the generic version of imatinib mesylate capsules (http://www.
Debulking large lesions is helpful when adjuvant therapy with imatinib mesylate is contemplated.
The patient was started on imatinib mesylate 400 mg daily and is on regular follow up.
These advances led to the development of molecular targeted therapy for adjuvant and neoadjuvant protocols, using tyrosine kinase inhibitors like imatinib mesylate.